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Abstract
Background: Late gadolinium enhanced cardiovascular magnetic resonance (LGE-CMR) has excellent specificity,
sensitivity and diagnostic accuracy for differentiating between ischemic cardiomyopathy (ICM) and non-ischemic
dilated cardiomyopathy (NICM). CMR first-pass myocardial perfusion imaging (perfusion-CMR) may also play role in
distinguishing heart failure of ischemic and non-ischemic origins, although the utility of additional of stress perfusion
imaging in such patients is unclear. The aim of this retrospective study was to assess whether the addition of adenosine
stress perfusion imaging to LGE-CMR is of incremental value for differentiating ICM and NICM in patients with severe left
ventricular systolic dysfunction (LVSD) of uncertain etiology.
Methods: We retrospectively identified 100 consecutive adult patients (median age 69 years (IQR 59–73)) with severe
LVSD (mean LV EF 26.6 ± 7.0%) referred for perfusion-CMR to establish the underlying etiology of heart failure. The cause
of heart failure was first determined on examination of CMR cine and LGE images in isolation. Subsequent examination of
complete adenosine stress perfusion-CMR studies (cine, LGE and perfusion images) was performed to identify whether
this altered the initial diagnosis.
Results: On LGE-CMR, 38 patients were diagnosed with ICM, 46 with NICM and 16 with dual pathology. With perfusion-
CMR, there were 39 ICM, 44 NICM and 17 dual pathology diagnoses. There was excellent agreement in diagnoses
between LGE-CMR and perfusion-CMR (κ 0.968, p<0.001). The addition of adenosine stress perfusion images to
LGE-CMR altered the diagnosis in only two of the 100 patients.
Conclusion: The addition of adenosine stress perfusion-CMR to cine and LGE-CMR provides minimal incremental
diagnostic yield for determining the etiology of heart failure in patients with severe LVSD.
Keywords: Cardiovascular magnetic resonance, Heart failure, Late gadolinium enhancement, Adenosine stress perfusion,
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Background
Identifying the etiology of heart failure has important
management and prognostic implications [1]. Thera-
peutic strategies for ischemic cardiomyopathy (ICM)
include revascularisation and/or secondary prevention
measures such as antiplatelet and lipid lowering therap-
ies. Conversely, the management of non-ischemic dilated
cardiomyopathy (NICM) relies predominantly on pharma-
cological agents and device therapy [2]. Rarer causes of
NICM (e.g. sarcoid, amyloid, HIV) require treatment of the
underlying condition [3]. Importantly survival rates are
poorer in those patients with heart failure of ischemic
origin [4]. Clinical guidelines suggest echocardiography as
the initial investigation of choice for evaluation of chronic
heart failure [1, 5]. In many instances, echocardiography
may reliably establish the underlying cause of heart failure.
Myocardial regional wall motion abnormalities alone, how-
ever, may not distinguish heart failure of ischemic origin
from NICM, since segmental wall motion abnormalities
may accompany both [6]. Where echocardiography does
not clearly identify the etiology of chronic heart failure, car-
diac magnetic resonance imaging (CMR) is advantageous
[1], owing to its capacity to detect evidence of myocardial
infarction and non-ischemic fibrosis and assess ischemia
and viability in a single examination [7].
Late gadolinium enhanced CMR (LGE-CMR) has been
shown to be non-inferior (and indeed may be superior)
to coronary angiography in differentiating heart failure
due to coronary artery disease (CAD) from NICM [8, 9].
Subendocardial LGE is present in CAD, whereas patients
with NICM have either no LGE or mid-wall late en-
hancement that does not correspond to a coronary ar-
tery territory (Fig. 1) [9]. Patients with heart failure and
a history of ischemic heart disease have a high preva-
lence of LGE visible on CMR (88% in one report) [10].
This suggests a high likelihood that LGE-CMR will yield
a diagnosis of ICM by hyperenhancement patterns alone,
without the need for additional perfusion imaging. Fol-
lowing myocardial infarction, the presence of LGE
affecting ≤50% of the thickness of the myocardium
predicts the likelihood of functional recovery in response
to revascularisation of the affected coronary territory
[11, 12]. In NICM, the presence of mid-wall fibrosis is
also of prognostic value, being an independent predictor
of cardiovascular and all-cause mortality [13].
CMR first-pass myocardial perfusion imaging (perfusion-
CMR) has been shown in several large studies to have
excellent sensitivity and specificity for detection of CAD
and may thus play a role in distinguishing heart failure of
ischemic and non-ischemic origins [14, 15]. However, the
added value of adenosine stress perfusion-CMR in subjects
with severe left ventricular systolic dysfunction (LVSD) has
not been investigated previously. Given that LGE-CMR
alone has excellent specificity (96%), sensitivity (100%) and
diagnostic accuracy (95%) for differentiating between ICM
and NICM [8], the utility of additional of stress perfusion
imaging in such patients is questionable.
Adenosine stress perfusion-CMR imaging adds time
(approximately 15 min added time for the perfusion-
CMR protocol) and expense to the CMR protocol, due
to the need for additional electrocardiograms, adenosine
preparations, infusion pumps and lines, as well as
physician-supervision. Undesirable symptoms and po-
tentially serious complications may occur with adenosine
infusion, albeit infrequently [16–19]. These include
wheeze secondary to bronchospasm, Mobitz II 2nd or
3rd degree atrioventricular block, and angina requiring
sublingual nitrates [17]. Furthermore, in patients with
heart failure, there is impairment of adenosine receptor
expression and signal-transduction [20], which may
diminish the hemodynamic response for stress perfusion
assessment, compromising diagnostic confidence.
In our regional cardiac centre, over 1000 clinical perfu-
sion-CMR studies are performed annually. Approximately
10% of these are to identify the cause of heart failure, and
despite a lack of evidence of additional benefit, stress per-
fusion is usually requested and performed.
The aim of this retrospective study was to assess
whether the addition of adenosine stress perfusion im-
aging to LGE-CMR is of incremental value for differenti-
ating ICM and NICM in patients with severe LVSD of
uncertain etiology.
Methods
Study population
We retrospectively identified 100 consecutive adult
patients with severe LVSD on echocardiography, re-
ferred for perfusion-CMR to ascertain the underlying
etiology of heart failure. Patients were scanned between
April 2015 and March 2016. Severe LVSD was defined
as a left ventricular ejection fraction (LV EF) ≤35% and
was confirmed by CMR volumetric and functional ana-
lysis prior to inclusion in the study. Participants’ past
medical history, medications, electrocardiographic data,
resting pulse and blood pressure were recorded at the
time of the CMR.
Fig. 1 Illustration of typical patterns of LGE seen in NICM and ICM.
White areas within the myocardium represent LGE. a Mid-wall LGE is
commonly seen in NICM, whereas b a subendocardial distribution of
LGE is typical in ICM
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The study was approved as a clinical audit and ethics
approval was deemed unnecessary.
CMR image acquisition
Clinical perfusion-CMR studies were undertaken on either
a 1.5 T (Siemens Avanto, Erlangen, Germany) or 3 T scan-
ner (Siemens Skyra, Erlangen, Germany). Cardiac volumes
and function were performed using standard CMR tech-
niques as previously described by our group [21]. For
stress perfusion, adenosine (140mcg/kg/min, increased up
to a maximum of 210mcg/kg/min to achieve a satisfac-
tory haemodynamic stress response) [18] was infused
for 3–5 min. Patients underwent pulse, blood pressure
and pulse oximetry monitoring at baseline and at 1-min
intervals during adenosine infusion. Symptomatic response
to adenosine was documented. During peak stress a bolus
of gadolinium-based contrast (Gadoterate meglumine,
Dotarem, Guerbet LLC, France) was injected (0.1 mmol/kg
at 1.5 T and 0.075 mmol/kg at 3 T), followed by a 20 mL
bolus of normal saline, at a rate of 5 mL/s and perfusion
images were acquired using a saturation recovery gradient
echo pulse sequence. Adenosine infusion was then discon-
tinued and a complete short axis cine stack was performed
before rest perfusion images were acquired following
administration of a second bolus of gadolinium-based con-
trast agent (total dose 0.15 mmol/kg). LGE images in 3 long
axis views and a complete short axis stack were acquired
after a further delay of 5–10 min.
CMR image analysis
Scans were anonymized and sent to a separate worksta-
tion for analysis which was performed blinded to all
patient details, by two specialists in CMR (JRA and JK)
as recommended by expert consensus [22]. No clinical in-
formation was made available prior to or during image
analysis. Definitions for etiology of severe LVSD were pre-
defined as “ischemic”, “non-ischemic” or “dual-pathology”
(having both ischemic and non-ischemic components and
where the extent of infarction and/or ischemia did not
explain the degree of LVSD). Image quality was rated as
“good”, “moderate”, “poor” or “not-analyzable” for each
modality. A two-stage process was employed for image
analysis. The etiology of severe LVSD was determined first
determined by consensus between JRA and JK after exam-
ination of cine and LGE images. Following this, the perfu-
sion sequences were interpreted with the cine and LGE
images and it was recorded whether the etiology of LVSD
changed depending on the presence of reversible perfu-
sion defects.
Invasive coronary angiography
Coronary angiograms were examined in those patients
in the cohort who underwent angiography on clinical
grounds. Images were analyzed blinded to patient details
and CMR image interpretation results by an experienced
cardiologist (GPM). Coronary artery disease was pre-
defined as being present if a coronary artery stenosis of
≥50% the luminal diameter of the artery was observed
and was noted as severe if stenosis severity was >70%.
Statistical analyses
Normality was assessed using Kolmogorov-Smirnov tests,
histograms, and Q-Q plots. Continuous data were
expressed as mean ± standard deviation, if normally dis-
tributed. Non-parametric variables were expressed as me-
dian and interquartile range. One-way analysis of variance
(ANOVA) was used to compare normal data and the
Independent-Samples Kruskal-Wallis test for non-normal
data between groups. The Kappa statistic was used as a
measure of agreement between the components of the
CMR scans with and without stress perfusion. Statistical
analysis was undertaken using SPSS version 20.0 software.
Results
Baseline characteristics
The study group consisted of 100 patients referred for
clinical stress perfusion-CMR to investigate the etiology
of severe LVSD. Demographic characteristics and CMR
volumetric and functional data are shown in Table 1.
The mean LV EF of the cohort was 26.6 ± 7.0% and
there were no significant differences in LV function or
volumes between patients with a diagnosis of ICM,
NICM or dual pathology (Table 1).
Etiology of LVSD by combined cine plus LGE-CMR
Image quality was excellent or good in 98 and poor in 2
studies. Thirty-eight patients were classified as having
ischemic, 46 non-ischemic and 16 dual pathology as the
cause of LVSD (Table 2). Fifty-three patients had subendo-
cardial or transmural hyperenhancement consistent with
previous myocardial infarction. Forty-nine (80%) patients
with NICM or dual pathology had evidence of mid-wall
hyperenhancement on LGE-CMR; the other 13 had no
visible LGE. The vast majority (n = 15, 94%) of patients
with dual pathology had a combination of hyperenhance-
ment patterns (subendocardial/transmural and mid-wall).
Etiology of LVSD by complete stress perfusion-CMR studies
Image quality for first-pass perfusion was rated as good
or excellent in 99 and poor in 1 patient. There were
reversible perfusion defects in 23/54 (43%) patients with
infarction and in 1 patient with no LGE. There was
excellent agreement in diagnoses between LGE-CMR
and perfusion-CMR (κ 0.968, p=<0.001) (Table 2), yield-
ing a change in diagnosis from LGE-CMR in only 2
cases. In the first of these (78-year-old male, LV EF
26%), the LGE-CMR diagnosis was NICM. There was
global LV hypokinesis with basal inferoseptal mid-wall
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LGE (Fig. 2a). The perfusion-CMR diagnosis was dual
pathology as an inferolateral subendocardial perfusion
abnormality was visualised, suggestive of ischemia
(Fig. 2b), but not severe enough to account for the
degree of LV impairment observed. In the second case
(a 77-year-old female), the LGE-CMR diagnosis was
NICM: image quality for LGE imaging was rated as
poor (though still considered diagnostic), and no enhance-
ment was visualised (Fig. 3a). The diagnosis by perfusion-
CMR was ICM with demonstration of a subendocardial
basal and mid LV anteroseptal perfusion defect (Fig. 3b).
Subsequently coronary angiography revealed a significant
LAD stenosis (Fig. 3c) and the patient underwent
revascularisation.
Angiographic findings
Thirty-two of the patients underwent coronary angiog-
raphy after CMR. The vast majority (n = 30, 93.8%) of
these showed significant CAD. Both patients who
underwent angiography that did not reveal significant
CAD had LGE-CMR and perfusion-CMR diagnoses of
NICM. LGE-CMR had a sensitivity of 87% for
predicting significant CAD in subjects with severe
LVSD, identifying ICM or dual pathology in 26/30
patients with significant CAD on angiography. Sensitiv-
ity of perfusion-CMR for predicting significant CAD
was 90% (27/30 patients with significant CAD identified
as having ICM or dual pathology). Only three cases of
CAD identified by angiography were not detected by
either LGE-CMR or perfusion-CMR (Table 3). In two
of these, the degree of coronary disease was not
deemed severe enough to alone account for the degree
of LV impairment.
Discussion
This study is the first to evaluate the incremental
value of perfusion-CMR over LGE-CMR in identifying
the etiology of heart failure in patients with severe
Table 1 Baseline characteristics of the 100 study participants
All patients (n = 100) ICM (n = 39) NICM (n = 44) Dual pathology (n = 17) P-value
Median age (years) 69 (59–73) 69 (54–84) 69 (50–88) 69 (57–81) 0.984
Gender 77% M, 33% F 77% M, 33% F 70% M, 30% F 94% M, 6% F
SBP (mmHg) 134.7 ± 23.7 135.9 ± 24.4 132.0 ± 19.8 134.5 ± 30.7 0.715
DBP (mmHg) 79.9 ± 14.8 79.7 ± 13.2 80.3 ± 14.5 77.6 ± 20.2 0.824
Pulse rate (beats/min) 72.3 ± 14.1 69.9 ± 12.4 75.1 ± 16.3 71.9 ± 11.4 0.263
ACEI (%) 73 72 71 83 0.68
ARB (%) 13 19 9 8 0.426
Beta blocker (%) 82 84 76 92 0.419
Loop diuretic (%) 51 50 53 50 0.967
Thiazide diuretic (%) 1 0 3 0 0.519
Aldosterone antagonist (%) 28 38 24 17 0.283
Calcium channel antagonist (%) 5 3 3 17 0.144
Digoxin (%) 13 9 15 17 0.738
Ivabradine (%) 3 0 3 8 0.292
Creatinine (umol/L) 93 ± 24 96 ± 30 89 ± 19 95 ± 22 0.334
LVEF (%) 26.6 ± 7.0 27.2 ± 7.1 28.2 ± 6.4 23.5 ± 6.5 0.095
LVEDVi (mL/m2) 139 ± 35 137.2 ± 33.3 135.0 ± 40.5 152.0 ± 29.5 0.406
LVESVi (mL/m2) 104 ± 34 101.5 ± 33.8 97.5 ± 36.1 117.6 ± 29.2 0.133
Table 2 Cause of LVSD diagnosed by LGE-CMR and perfusion-CMR
LGE-CMR PERFUSION-CMR
Cause of LVSD (n)
Ischemic 38 39 K = 0.968, p < 0.001
Non-ischemic 46 44
Dual pathology 16 17
Fig. 2 a Two-chamber LGE image with inferior LV mid-wall
hyperenhancement (arrow). b First-pass perfusion-CMR image
demonstrating an inferolateral subendocardial perfusion
abnormality (arrow)
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LVSD. We have shown that the vast majority of
patients with LVSD are identified by LGE and that
the addition of stress perfusion only identified one
additional patient with important ischemia requiring
revascularisation.
LGE-CMR versus perfusion-CMR
LGE-CMR is a proven technique for determining the
etiology of heart failure [9], having been shown in previ-
ous studies to accurately differentiate between ICM and
NICM [23, 24]. Clinical guidelines advocate the use of
LGE-CMR in heart failure, when echocardiography is
non-diagnostic [1, 25]. The utilisation of LGE-CMR in
this context is known to have significant clinical impact;
influencing patient management, clinical decisions and
diagnoses in 65% of patients in one study [26]. When
mid-wall LGE is present in NICM, this portends a
poorer prognosis [13]. A high proportion of our patients
with NICM had mid-wall LGE in comparison to the
published literature (80 versus 30% in Gulati et al.) [13].
This is probably the result of our study group being
older (69 (59–73) versus 51 ± 15 years) and with much
poorer LV systolic function (mean LV EF 27.5 ± 6.8%
versus 37.2 ± 13.1%) [13].
Perfusion-CMR is highly accurate for identifying myo-
cardial ischemia due to CAD [15, 27, 28]. No published
data exist, however, characterising the role of perfusion-
CMR in determining the etiology of severe LVSD. Despite
this, it is routine in our institution to undertake full
adenosine stress perfusion-CMR studies for identifying
the cause of heart failure in patients with newly diagnosed
severe LVSD. The EuroCMR registry, which includes data
on more than 27,000 consecutive CMR studies from over
15 European countries, showed that almost a third
(29.3%) of CMR studies include adenosine stress perfusion
imaging [16]. Data on the specific indications for
perfusion-CMR are not presented in the EuroCMR regis-
try, but it is likely that a significant number of these stud-
ies were also performed in subjects with severe LVSD.
Adenosine stress perfusion imaging adds time and ex-
pense to the CMR protocol. Seventy five to 100% of all
complications associated with CMR occur due to admin-
istration of pharmacologic stress agents [16]. There is
also evidence to suggest that patients with heart failure
Fig. 3 a Mid short-axis LGE window; there is no hyperenhancement to
suggest myocardial infarction. b First-pass perfusion-CMR image
showing a mid LV anteroseptal reversible perfusion defect (arrow). c
The corresponding coronary angiogram image; there is a chronic total
occlusion of the proximal-mid left anterior descending artery (arrow)
Table 3 Summary of angiographic and CMR findings in patients with angiographically-determined significant CAD and a diagnosis
of NICM on CMR
Angiogram findings Non-stress CMR findings Perfusion-CMR findings Comments
Moderate (50% stenosis) LCx disease. Global LV hypokinesis. Severe
bi-atrial dilatation with MR
and TR.
Mid-wall LGE present.
No perfusion abnormality detected. CAD likely coincident and not
main etiological factor.
Mild left mainstem (~30%)
and severe RCA disease.
Global LVSD and marked
intraventricular dyssynchrony.
Severely dilated LA. Moderate MR.
No LGE.
No perfusion abnormality detected. CAD likely coincident and not
main etiological factor.
Patient condition improved
with intensive medical therapy
(now NYHA class I).
Three-vessel coronary disease.
Severe LAD and LCx disease,
moderate RCA disease.
Severe hypokinesis starting in the
midanterior segment, becoming akinetic
in the apex.
No valve disease.
No LGE.
No perfusion abnormality detected. True false-negative CMR.
Patient underwent CABG.
Gulsin et al. BMC Cardiovascular Disorders  (2017) 17:98 Page 5 of 7
exhibit a diminished response to adenosine due to down
regulation of adenosine receptors in the failing myocar-
dium [16]. Clearly the role of perfusion-CMR in deter-
mining the etiology of heart failure should be subject to
scrutiny before routine implementation in clinical
practice.
We found excellent agreement between the causes of
LVSD diagnosed by LGE-CMR and by perfusion-CMR,
suggesting that perfusion-CMR is of limited additional
benefit over LGE-CMR for the specific indication of
identifying the etiology of heart failure. In only two of
our 100 patients did perfusion-CMR alter the diagnosis
established by LGE-CMR (and led to a meaningful change
in patient management, i.e. revascularisation, in only one
patient). Perfusion-CMR did, however, identify reversible
ischemia in 43% of patients with a non-stress-CMR diag-
nosis of ICM/dual pathology. Whilst this did not alter the
diagnosis in these patients it may have implications on
clinical management. Generally both LGE-CMR and
perfusion-CMR had excellent sensitivity for detection of
CAD. Importantly these analyses were made entirely
blinded to patient details and medical history, which in
clinical practice would ordinarily guide risk stratification
and decision-making and raise suspicion of CAD.
Clinical implications
Our study demonstrates that stress perfusion-CMR is of
minimal incremental benefit in diagnosing the cause of
severe LVSD. It is therefore contentious whether stress
testing should be routinely performed in this context.
Patients with severe LVSD attributed to previous infarc-
tion on LGE-CMR with a likelihood of functional
recovery often undergo coronary angiography and revas-
cularisation. However the role of revascularization in
patients with ICM in the absence of symptoms is con-
troversial. In the STITCH trial, there was no significant
difference in outcomes when patients with heart failure
and coronary artery disease underwent surgical revascu-
larization versus medical therapy alone [29]. In such in-
stances perfusion-CMR is therefore of limited added
benefit. In cases of severe LVSD where LGE-CMR ex-
cludes ICM by patterns of hyperenhancement specific to
NICM, exposing the patient to risks of invasive angiog-
raphy could be unwarranted as the likelihood of identify-
ing significant coronary disease is low. On the other
hand, we found that perfusion-CMR identified additional
ischemia in half our patients diagnosed with ICM. In
these cases, perfusion-CMR may influence subsequent
management, although the benefit of routine revasculari-
sation in the absence of angina over medical manage-
ment is far from clear [29].
The present study challenges the incremental role of
perfusion-CMR over LGE-CMR for diagnosing the eti-
ology of heart failure in severe LVSD. Clinical guidelines
do not specifically recommend perfusion-CMR for this
purpose [1, 5]. However, observations from our own
clinical practice and EuroCMR registry data suggest that
perfusion-CMR is routinely utilised to determine the
cause of severe LVSD when echocardiography is non-
diagnostic [16]. Exposing patients in these cases to the
added risks of adenosine infusion, together with increas-
ing MR scanning times and expense are probably unjus-
tified at present.
Limitations
The retrospective and single-centre design limits the
strength of this study, as does the relatively small sample
size. Coronary angiography, as the reference standard
for CAD, was not performed on all subjects in the co-
hort to exclude CAD. Computed tomography coronary
angiography can be used to reliably exclude the presence
of CAD but will be difficult to interpret in high risk pa-
tients with coronary calcium and does not provide prog-
nostic information related to LGE [30].
Conclusions
Adenosine stress perfusion-CMR is of minimal add-
itional benefit to cine and LGE-CMR for determining
the etiology of heart failure in patients with severe
LVSD. Prospective studies are required to define the role
of perfusion-CMR in heart failure and identify those
patients most likely to benefit from the addition of per-
fusion imaging to LGE-CMR.
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